Cloud-Based Informatics Enable Smarter Antibiotic Use and Infection Control

  23 December 2020

Over the past few decades, overuse of antibiotics has contributed to the increasing development of antibiotic-resistant so-called “superbugs”— i.e., dangerous bacterial and fungal infections that are now responsible for more than 2.8 million infections and 35,000 deaths in the United States each year. Even amid the ongoing COVID-19 pandemic, antimicrobial resistance (AMR) in hospitalized patients is still a major risk, one that can actually be further exacerbated by COVID treatment. A recent U.S. multi-center study reported that 72% of COVID-19 patients received antibiotics even when not clinically indicated.

Most antibiotics are prescribed before or without knowing the pathogen and its susceptibility to antibiotics, and therein lies the crux of the matter. Before administering antibiotics, healthcare workers should be aware of what specific pathogen(s) they are treating because different bugs may respond differently to antibiotics, particularly if drug-resistant pathogens are encountered. Overuse or inappropriate use of antibiotics clearly drives the evolution of AMR and can lead to the development of drug-resistant infections in patients.

Further reading: MedTech Intelligence
Author(s): Oliver Schacht
Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

LifeArc

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS





Ambassador Network

Join the AMR Insights Ambassador Network today!

Connect to over 650 AMR professionals and students in 65 countries!

Register

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed